UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 36

Sortiert nach

BEPS-Herausforderungen für die Unternehmen

1, 2015

Volltextzugriff (PDF)

BEPS aus der Sicht der Unternehmen

BEPS-Herausforderung für die Unternehmen, 2015, Vol.44, p.11-22

2015

Volltextzugriff (PDF)

Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines

JAMA oncology, 2019-04, Vol.5 (4), p.523

2019

Volltextzugriff (PDF)

Hospital Volume Threshold for the Treatment of Retroperitoneal Sarcoma

Anticancer research, 2019-04, Vol.39 (4), p.2007-2014

2019

Volltextzugriff (PDF)

Reducing INS-IGF1 signaling protects against non-cell autonomous vesicle rupture caused by SNCA spreading

Autophagy, 2020-05, Vol.16 (5), p.878-899

2020

Volltextzugriff (PDF)

Efficient Electronic Communication of Two Ruthenium Centers through a Rigid Ditopic N-Heterocyclic Carbene Linker

Chemistry : a European journal, 2013-12, Vol.19 (51), p.17517-17527

2013

Volltextzugriff (PDF)

α-Synuclein Strains: Does Amyloid Conformation Explain the Heterogeneity of Synucleinopathies?

Biomolecules (Basel, Switzerland), 2021-06, Vol.11 (7), p.931

2021

Volltextzugriff (PDF)

A case study of real-world tailpipe emissions for school buses using a 20% biodiesel blend

The Science of the total environment, 2007-10, Vol.385 (1), p.146-159

2007

Volltextzugriff (PDF)

Mitochondrial dysfunction, peroxidation damage and changes in glutathione metabolism in PARK6

Neurobiology of disease, 2007-02, Vol.25 (2), p.401-411

2007

Volltextzugriff (PDF)

C. elegans Models to Study the Propagation of Prions and Prion-Like Proteins

Biomolecules (Basel, Switzerland), 2020-08, Vol.10 (8), p.1188

2020

Volltextzugriff (PDF)

Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity

Molecular cancer therapeutics, 2016-04, Vol.15 (4), p.583-592

2016

Volltextzugriff (PDF)

Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors In Vitro and In Vivo

Clinical cancer research, 2019-02, Vol.25 (4), p.1404-1414

2019

Volltextzugriff (PDF)

BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling‐dependent tumor growth in mouse models

International journal of cancer, 2017-01, Vol.140 (2), p.449-459

2017

Volltextzugriff (PDF)

Cyclophilin A is a ligand for RAGE in thrombo-inflammation

Cardiovascular research, 2024-03, Vol.120 (4), p.385-402

2024

Volltextzugriff (PDF)

Real-world PM, NOₓ, CO, and ultrafine particle emission factors for military non-road heavy duty diesel vehicles

Atmospheric environment (1994), 2011-05, Vol.45 (15), p.2603-2609

2011

Volltextzugriff (PDF)

Abstract 5873: BAY-3827, a selective inhibitor of AMPK for the evaluation of the role of AMPK in Myc-dependent tumors

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.5873-5873

2018

Volltextzugriff (PDF)

Intravenous and oral levetiracetam in patients with a suspected primary brain tumor and symptomatic seizures undergoing neurosurgery: the HELLO trial

Acta neurochirurgica, 2012-02, Vol.154 (2), p.229-235

2012

Volltextzugriff (PDF)

Abstract 287: BAY 1816032, a novel BUB1 kinase inhibitor with potent antitumor activity

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.287-287

2017

Volltextzugriff (PDF)

Abstract 1887: Preclinical evaluation of a novel interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor in combination with PI3K inhibitor copanlisib or BTK inhibitors in ABC-DLBCL

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.1887-1887

2018

Volltextzugriff (PDF)

The In-Plume Emission Test Stand: An Instrument Platform for the Real-Time Characterization of Fuel-Based Combustion Emissions

Journal of the Air & Waste Management Association (1995), 2009-12, Vol.59 (12), p.1437-1445

2009

Volltextzugriff (PDF)

In-Plume Emission Test Stand 2: Emission Factors for 10- to 100-kW U.S. Military Generators

Journal of the Air & Waste Management Association (1995), 2009-12, Vol.59 (12), p.1446-1457

2009

Volltextzugriff (PDF)

Abstract 3090: Novel Mps1 kinase inhibitors with potent anti-tumor activity

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.3090-3090

2015

Volltextzugriff (PDF)

Abstract 2050: BAY 1125976, a highly selective and potent allosteric AKT1/2 inhibitor, for the treatment of cancers with aberrations in the PI3K-AKT-mTOR pathway

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.2050-2050

2013

Volltextzugriff (PDF)

Real-world PM, NO x, CO, and ultrafine particle emission factors for military non-road heavy duty diesel vehicles

Atmospheric environment (1994), 2011, Vol.45 (15), p.2603-2609

2011

Volltextzugriff (PDF)

1 – 25 von 36

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(29)
Mit Volltextzugriff
(30)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

BEPS-Herausforderungen für die Unternehmen

BEPS aus der Sicht der Unternehmen

Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines

Hospital Volume Threshold for the Treatment of Retroperitoneal Sarcoma

Reducing INS-IGF1 signaling protects against non-cell autonomous vesicle rupture caused by SNCA spreading

Efficient Electronic Communication of Two Ruthenium Centers through a Rigid Ditopic N-Heterocyclic Carbene Linker

α-Synuclein Strains: Does Amyloid Conformation Explain the Heterogeneity of Synucleinopathies?

A case study of real-world tailpipe emissions for school buses using a 20% biodiesel blend

Inherited TP53 Variants and Risk of Prostate Cancer

Mitochondrial dysfunction, peroxidation damage and changes in glutathione metabolism in PARK6

C. elegans Models to Study the Propagation of Prions and Prion-Like Proteins

Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity

Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors In Vitro and In Vivo

BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling‐dependent tumor growth in mouse models

Cyclophilin A is a ligand for RAGE in thrombo-inflammation

Real-world PM, NOₓ, CO, and ultrafine particle emission factors for military non-road heavy duty diesel vehicles

Abstract 5873: BAY-3827, a selective inhibitor of AMPK for the evaluation of the role of AMPK in Myc-dependent tumors

Intravenous and oral levetiracetam in patients with a suspected primary brain tumor and symptomatic seizures undergoing neurosurgery: the HELLO trial

Abstract 287: BAY 1816032, a novel BUB1 kinase inhibitor with potent antitumor activity

Abstract 1887: Preclinical evaluation of a novel interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor in combination with PI3K inhibitor copanlisib or BTK inhibitors in ABC-DLBCL

The In-Plume Emission Test Stand: An Instrument Platform for the Real-Time Characterization of Fuel-Based Combustion Emissions

In-Plume Emission Test Stand 2: Emission Factors for 10- to 100-kW U.S. Military Generators

Abstract 3090: Novel Mps1 kinase inhibitors with potent anti-tumor activity

Abstract 2050: BAY 1125976, a highly selective and potent allosteric AKT1/2 inhibitor, for the treatment of cancers with aberrations in the PI3K-AKT-mTOR pathway

Real-world PM, NO x, CO, and ultrafine particle emission factors for military non-road heavy duty diesel vehicles

Suchergebnisse filtern